Biodexa Pharmaceuticals Plc ADR (BDRX)

$6.70 +0.03 (0.45%)
Market Cap 4.15M
Revenue (ttm) 0.00
Net Income (ttm) -7.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.04
Volume 15,800
Avg Vol 37,995
Day's Range N/A - N/A
Shares Out 620,000.00
Stochastic %K 52%
Beta 0.91
Analysts Sell
Price Target $18.00

Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 29 2048 0180
Address:
1 Caspian Point, Caspian Way, Cardiff, United Kingdom
TradingBeasts
TradingBeasts Oct. 3 at 7:39 PM
$BDRX swing
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 5:53 PM
$FGI $BDRX $NAAS $SLXN Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve!
0 · Reply
Metal_Health
Metal_Health Oct. 3 at 3:20 PM
$BDRX can't wait'll this blows up...got to do the DD but also have firm patience.
0 · Reply
BiotechBonesaw
BiotechBonesaw Oct. 3 at 1:25 PM
$BDRX holy moly on both the dilution & pipeline potential! Following this for the right buying opportunity ⏰
1 · Reply
BiotechBonesaw
BiotechBonesaw Oct. 3 at 1:16 PM
$BDRX officially tracking this. Once the dilution is done, this has a very potent pipeline that will read out a phase 3 & phase 2 IN the next couple of years 🤔
0 · Reply
HouseOfTheDragons
HouseOfTheDragons Oct. 3 at 2:35 AM
Looks like volume & momentum could be shifting in to ASTC! Tiny float getting a lot of attention and could explode upwards on volume. Watchers on ASTC are growing very fast and it could be the potential top runner for this week! Starting its 300% run - keep it on watch! Also watching for breakout: $BDRX $BDTX $BE $BGLC ---
0 · Reply
MexaTraders
MexaTraders Oct. 2 at 8:18 PM
Ticker ASTC is starting to move. 6.40$ break could send ASTC into a potential HALT-up or squeeze. It is breaking out and starting its 300% run now! Can we see a massive run of ASTC into close? Micro float Squeezer is making a move! $ILLR $KITT $QNRX $BDRX )(
0 · Reply
1Spartantrade1
1Spartantrade1 Oct. 2 at 6:27 PM
Massive merger news 3 days ago on NITO! NITO has a low share count like TTNP (BTTC) does. TTNP ran 400% today. Can NITO also run 400%? Make sure to take profits. Lets see if NITO halts up today when people realize. $DRMA $VSTD $FGI $BDRX 🔥
0 · Reply
Love_To_Learn
Love_To_Learn Oct. 2 at 10:45 AM
$BGFV u being halted on 1.44********** its BEUD NUMBER $BDRX also the 1.55****** for markets i placed that has access to much higher pt startign with 8.62/8.65 then higher above 20 if chosenanyway key halt here for markets to set the tone
1 · Reply
Love_To_Learn
Love_To_Learn Oct. 1 at 7:41 PM
$BDRX making changes to your 5.09* @ your lower range beud changing few things up on the go wil impact some of the 7's range as well to keep u reasonable need to also release that 2.12 from the bottom range and 2.21* segment it to not cause harm @ this moment
0 · Reply
Latest News on BDRX
Interim results for the six months ended June 30, 2025

Sep 12, 2025, 8:30 AM EDT - 22 days ago

Interim results for the six months ended June 30, 2025

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

Sep 8, 2025, 7:00 AM EDT - 26 days ago

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Aug 18, 2025, 8:30 AM EDT - 6 weeks ago

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

ADR Ratio Change Effective

Jul 31, 2025, 9:30 AM EDT - 2 months ago

ADR Ratio Change Effective

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

Jul 28, 2025, 7:00 AM EDT - 2 months ago

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

ADR Ratio Change

Jul 15, 2025, 4:30 PM EDT - 2 months ago

ADR Ratio Change

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Jul 14, 2025, 8:30 AM EDT - 2 months ago

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Results of Annual General Meeting

Jun 27, 2025, 8:30 AM EDT - 3 months ago

Results of Annual General Meeting

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Jun 25, 2025, 8:30 AM EDT - 3 months ago

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Jun 23, 2025, 8:30 AM EDT - 3 months ago

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Jun 18, 2025, 7:00 AM EDT - 3 months ago

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Result of General Meeting

Jun 11, 2025, 4:30 PM EDT - 4 months ago

Result of General Meeting

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Jun 4, 2025, 8:30 AM EDT - 4 months ago

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Shareholder Update

May 30, 2025, 8:30 AM EDT - 4 months ago

Shareholder Update

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

May 22, 2025, 4:30 PM EDT - 4 months ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

May 22, 2025, 8:30 AM EDT - 4 months ago

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

May 12, 2025, 8:30 AM EDT - 5 months ago

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

Notice of General Meeting

Apr 17, 2025, 8:30 AM EDT - 6 months ago

Notice of General Meeting

Preliminary Results for the Year Ended 31 December 2024

Apr 11, 2025, 8:30 AM EDT - 6 months ago

Preliminary Results for the Year Ended 31 December 2024

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Mar 19, 2025, 7:00 AM EDT - 7 months ago

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Mar 10, 2025, 8:30 AM EDT - 7 months ago

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Mar 6, 2025, 8:30 AM EST - 7 months ago

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Feb 24, 2025, 8:30 AM EST - 7 months ago

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Feb 13, 2025, 8:30 AM EST - 8 months ago

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Feb 12, 2025, 7:30 AM EST - 8 months ago

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Feb 10, 2025, 8:30 AM EST - 8 months ago

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Jan 22, 2025, 8:30 AM EST - 9 months ago

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Nov 21, 2024, 7:35 AM EST - 11 months ago

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

Nov 12, 2024, 8:48 AM EST - 11 months ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Shareholders to Reach Out

Oct 31, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biodexa Pharmaceuticals Plc (BDRX) and Encourages Investors to Learn More About the Investigation

Oct 30, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biodexa Pharmaceuticals Plc (BDRX) and Encourages Investors to Learn More About the Investigation

Biodexa Pharmaceuticals Plc (BDRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Oct 29, 2024, 10:00 AM EDT - 1 year ago

Biodexa Pharmaceuticals Plc (BDRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Reach Out

Oct 28, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Connect

Oct 27, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Connect

Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer

Oct 17, 2024, 7:30 AM EDT - 1 year ago

Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer

Biodexa Announces Successful Appeal of Nasdaq Delisting

Oct 15, 2024, 4:15 PM EDT - 1 year ago

Biodexa Announces Successful Appeal of Nasdaq Delisting

Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma

Oct 4, 2024, 8:30 AM EDT - 1 year ago

Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma

Interim results for the six months ended June 30, 2024

Sep 26, 2024, 8:30 AM EDT - 1 year ago

Interim results for the six months ended June 30, 2024

TradingBeasts
TradingBeasts Oct. 3 at 7:39 PM
$BDRX swing
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 5:53 PM
$FGI $BDRX $NAAS $SLXN Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve!
0 · Reply
Metal_Health
Metal_Health Oct. 3 at 3:20 PM
$BDRX can't wait'll this blows up...got to do the DD but also have firm patience.
0 · Reply
BiotechBonesaw
BiotechBonesaw Oct. 3 at 1:25 PM
$BDRX holy moly on both the dilution & pipeline potential! Following this for the right buying opportunity ⏰
1 · Reply
BiotechBonesaw
BiotechBonesaw Oct. 3 at 1:16 PM
$BDRX officially tracking this. Once the dilution is done, this has a very potent pipeline that will read out a phase 3 & phase 2 IN the next couple of years 🤔
0 · Reply
HouseOfTheDragons
HouseOfTheDragons Oct. 3 at 2:35 AM
Looks like volume & momentum could be shifting in to ASTC! Tiny float getting a lot of attention and could explode upwards on volume. Watchers on ASTC are growing very fast and it could be the potential top runner for this week! Starting its 300% run - keep it on watch! Also watching for breakout: $BDRX $BDTX $BE $BGLC ---
0 · Reply
MexaTraders
MexaTraders Oct. 2 at 8:18 PM
Ticker ASTC is starting to move. 6.40$ break could send ASTC into a potential HALT-up or squeeze. It is breaking out and starting its 300% run now! Can we see a massive run of ASTC into close? Micro float Squeezer is making a move! $ILLR $KITT $QNRX $BDRX )(
0 · Reply
1Spartantrade1
1Spartantrade1 Oct. 2 at 6:27 PM
Massive merger news 3 days ago on NITO! NITO has a low share count like TTNP (BTTC) does. TTNP ran 400% today. Can NITO also run 400%? Make sure to take profits. Lets see if NITO halts up today when people realize. $DRMA $VSTD $FGI $BDRX 🔥
0 · Reply
Love_To_Learn
Love_To_Learn Oct. 2 at 10:45 AM
$BGFV u being halted on 1.44********** its BEUD NUMBER $BDRX also the 1.55****** for markets i placed that has access to much higher pt startign with 8.62/8.65 then higher above 20 if chosenanyway key halt here for markets to set the tone
1 · Reply
Love_To_Learn
Love_To_Learn Oct. 1 at 7:41 PM
$BDRX making changes to your 5.09* @ your lower range beud changing few things up on the go wil impact some of the 7's range as well to keep u reasonable need to also release that 2.12 from the bottom range and 2.21* segment it to not cause harm @ this moment
0 · Reply
Love_To_Learn
Love_To_Learn Oct. 1 at 6:25 PM
$BDRX changing your data read out for now
0 · Reply
Chokky
Chokky Sep. 30 at 12:31 PM
$BDRX
0 · Reply
Love_To_Learn
Love_To_Learn Sep. 30 at 10:45 AM
$BDRX need u soon
0 · Reply
Vulnerable
Vulnerable Sep. 29 at 4:08 PM
$PSTV @Love_To_Learn LOZLOZLOZ Mo has jokes. Mo is the short. Repeat that Mo is the short. These ongoing projections of super runners is a smoke screen. No fear shorting. No fear not being able to cover. Stop losses set and powder to buy if runs higher. BTW there will be some super runnners but they will not be stocks tagged by mo and they will be market caps under 1 millon with low float that he's in total control to manipulate. Don't forget pre destined by Mo, but always changing, but frequent stocks can't run because they are market keys..everything he says contradicts himself. $SLS $AKBA $BDRX
4 · Reply
Paraboljoker
Paraboljoker Sep. 29 at 1:41 PM
$WIMI Looks good $BDRX ww of $DWTX $INHD Swing
0 · Reply
LegendaryCharts
LegendaryCharts Sep. 28 at 3:43 PM
$PAVS Bullish reversal on this low float, Squeezing up , top watch for tomorrows gap up $BDRX recent bullish phase 3 news $DUO popped recently, watching $HOUR up to 10 soon imo
0 · Reply
mar29isol_stout
mar29isol_stout Sep. 27 at 7:17 PM
$BDRX
0 · Reply
DonCorleone77
DonCorleone77 Sep. 27 at 6:44 PM
$BDRX Biodexa Pharmaceuticals files $100M mixed securities shelf
0 · Reply
RAFN
RAFN Sep. 27 at 12:06 AM
$DOMH $ARTL $BDRX 6.00
0 · Reply
lecorb
lecorb Sep. 26 at 9:45 PM
$BDRX : Biodexa Pharmaceuticals files $100M shelf for flexible securities offerings
0 · Reply
StockRedBaron
StockRedBaron Sep. 26 at 9:12 PM
$BDRX UGGGGH $100 MILLION DILUTION I'm DONE with this CRAP company!
0 · Reply
Love_To_Learn
Love_To_Learn Sep. 26 at 1:01 PM
$BDRX * update pending
1 · Reply